Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Change in Accured Expenses (2016 - 2025)

CytomX Therapeutics' Change in Accured Expenses history spans 12 years, with the latest figure at $486000.0 for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 108.75% year-over-year to $486000.0; the TTM value through Dec 2025 reached -$3.0 million, up 68.33%, while the annual FY2025 figure was -$3.0 million, 68.33% up from the prior year.
  • Change in Accured Expenses reached $486000.0 in Q4 2025 per CTMX's latest filing, up from -$326000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.1 million in Q4 2021 to a low of -$7.4 million in Q1 2023.
  • Average Change in Accured Expenses over 5 years is -$1.1 million, with a median of -$1.3 million recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: surged 567.05% in 2021, then tumbled 932.12% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $8.1 million in 2021, then plummeted by 147.94% to -$3.9 million in 2022, then skyrocketed by 136.63% to $1.4 million in 2023, then plummeted by 490.03% to -$5.6 million in 2024, then soared by 108.75% to $486000.0 in 2025.
  • Per Business Quant, the three most recent readings for CTMX's Change in Accured Expenses are $486000.0 (Q4 2025), -$326000.0 (Q3 2025), and -$1.1 million (Q2 2025).